



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Miriam Michel
✉ miriam.michel@i-med.ac.at

[†]These authors have contributed equally to
this work and share first authorship

[‡]These authors have contributed equally to
this work and share senior authorship

RECEIVED 28 August 2025

ACCEPTED 29 August 2025

PUBLISHED 09 September 2025

CITATION

Muschel N, Höck M, Griesmaier E, Azim SA,
Ralser E, Schreiner C, Schermer E, Kiechl-
Kohlendorfer U, Mutz-Dehbalaie I and
Michel M (2025) Correction: Drug review:
mTOR-inhibitor therapy in fetal cardiac
rhabdomyoma—a tightrope walk.
Front. Pediatr. 13:1694368.
doi: 10.3389/fped.2025.1694368

COPYRIGHT

© 2025 Muschel, Höck, Griesmaier, Azim,
Ralser, Schreiner, Schermer, Kiechl-
Kohlendorfer, Mutz-Dehbalaie and Michel.
This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that
the original publication in this journal is cited,
in accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Correction: Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk

Nadine Muschel^{1†}, Michaela Höck^{2†}, Elke Griesmaier²,
Samira Abdel Azim¹, Elisabeth Ralser², Christina Schreiner²,
Elisabeth Schermer³, Ursula Kiechl-Kohlendorfer²,
Irene Mutz-Dehbalaie^{1†} and Miriam Michel^{3*‡}

¹Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria,

²Department of Paediatrics II (Neonatology), Medical University of Innsbruck, Innsbruck, Austria,

³Department of Paediatrics III (Cardiology, Pulmonology, Allergology and Cystic Fibrosis), Medical
University of Innsbruck, Innsbruck, Austria

KEYWORDS

adverse effects, fetal cardiac tumor, rhabdomyoma, sirolimus, re-entry tachycardia

A Correction on

Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a
tightrope walk

By Muschel N, Höck M, Griesmaier E, Azim SA, Ralser E, Schreiner C, Schermer E, Kiechl-
Kohlendorfer U, Mutz-Dehbalaie I and Michel M (2025). Front. Pediatr. 13:1649341. doi:
10.3389/fped.2025.1649341

The following **Acknowledgments** statement was erroneously omitted:

“The authors thank the patient and his family for their kind cooperation, and very
much regret the child’s adverse outcome. The authors thank E. Michel for manuscript
proofreading and T. Klenner for creating the graphic and formatting the tables.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not
necessarily represent those of their affiliated organizations, or those of the publisher,
the editors and the reviewers. Any product that may be evaluated in this article, or
claim that may be made by its manufacturer, is not guaranteed or endorsed by
the publisher.